Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
Helicobacter ; 23(2): e12476, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29504209

ABSTRACT

BACKGROUND: Recent studies of Lactobacillus delbrueckii subsp. bulgaricus GLB44 plus a proton-pump inhibitor (PPI) reported cures of more than 90% of patients with active Helicobacter pylori infections. AIM: To confirm the high H. pylori cure rates reported previously. METHOD: A pilot study was done in healthy H. pylori-infected volunteers using 3-gram sachet (3 billion cells) of L. delbrueckii GLB44 plus 22.3 mg of esomeprazole b.i.d., for 14 days. The result was determined by urea breath testing 4 weeks after therapy. Stopping rules required for ending enrollment if less than 3 of the first 10 subjects were cured. RESULTS: Nine subjects were entered and because all failed to achieve negative urea breath test, the stopping rule required the study to end. CONCLUSION: We were unable to confirm reports of achieving a high H. pylori cure rate with L. delbrueckii GLB44 plus a PPI.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Esomeprazole/therapeutic use , Helicobacter Infections/drug therapy , Helicobacter pylori/drug effects , Lactobacillus delbrueckii/physiology , Adult , Female , Helicobacter pylori/pathogenicity , Humans , Male
SELECTION OF CITATIONS
SEARCH DETAIL